Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: XENE) | Delayed: 35.47 -1.03 (2.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.50 | 52 Week High | $9.75 | |||
| Open | $36.62 | 52 Week Low | $5.65 | |||
| Day High | $36.62 | P/E | N/A | |||
| Day Low | $35.41 | EPS | $0.00 | |||
| Volume | 32,622 | |||||
